Evidence map›Paper›PMID 23894709›Full record

ArticleOncoimmunology2013

The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy.

José I Quetglas, Sandra Hervas-Stubbs, Cristian Smerdou

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

José I QuetglasDivision of Hepatology and Gene Therapy; Center for Applied Medical Research (CIMA); University of Navarra; Pamplona, Navarra, Spain.
Sandra Hervas-Stubbs
Cristian Smerdou
Gene Therapy Laboratory · FRChartered Institute of Management Accountants · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Do cancer patients responding to immunotherapy have immunological profiles that influence the therapeutic outcome, or do they develop efficient antitumor responses only upon immunotherapy? We came across this "chicken or the egg" dilemma when treating secondary liver tumors with Semliki Forest viruses expressing interleukin-12. In our system, the "egg," that is, the pre-treatment immunological profile, seemed to make the difference. The properties of an effective antitumor response were also defined.

Indexed as

alphaviruscancer immunotherapyIL-12IL-15Rαliver secondary tumor

Identifiers

PMID23894709
PMCPMC3716744
OpenAlexW2002468486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.